Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical rHDL for post-amputation diabetic foot wounds
ACTRN12619000269134Phase 2Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of reconstituted high-density lipoproteins in diabetic foot ulcer (DFU) and Abnormal wound healing (2 arms), sponsored by University of Adelaide. Primary endpoint: Percentage wound closure from baseline wound area. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
reconstituted high-density lipoproteins
03
Conditions
diabetic foot ulcer (DFU)Abnormal wound healing
Beyond the preview
Go deeper on ACTRN12619000269134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000269134.